GLP-1 receptor agonists delay gastric emptying, suppress glucagon secretion, and can reduce postprandial hyperglycemia, offering the potential to further optimize glucose control beyond what insulin-only closed-loop systems can achieve. This evidence concerns the gene GLP1R and Hyperglycemia.